invasive fungal infections
Conditions
Interventions
case series:No
Sponsors
Second Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who were hospitalized and used voriconazole in the Second Xiangya Hospital of Central South University from May 2014 to December 2020; 2. No gender limit, no age limit; 3. Confirmed, clinically diagnosed or suspected IFI and patients with high risk factors for fungal infection; 4. Monitor the plasma concentration of voriconazole at least once at steady state (after 3 days of administration).
Exclusion criteria
Exclusion criteria: 1. Patients who cannot obtain accurate voriconazole dosage and main clinical data; 2. Plasma exchange therapy was performed during the concentration determination; 3. Patients known to be allergic to voriconazole or any of its components; 4. It is judged by the investigator that it is not suitable to participate in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| trough concentration; | — |
Countries
China
Contacts
Public ContactYan Miao
Second Xiangya Hospital, Central South University
Outcome results
None listed